Cargando…

HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial

OBJECTIVE: To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA(1c)) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. RESEARCH DESIGN AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwan, Anita Y.M., Gerstein, Hertzel C., Basile, Jan, Xavier, Denis, Maldonado, Juan M., Raha, Sohini, Konig, Manige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2022
Materias:	Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918189/ https://www.ncbi.nlm.nih.gov/pubmed/35043140 http://dx.doi.org/10.2337/dc21-1160

Ejemplares similares

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2023)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
por: Dagenais, Gilles R., et al.
Publicado: (2020)

Responses to the Strengths and Difficulties Questionnaire predict HbA1c trajectories in children and adolescents with type 1 diabetes: a population-based study
por: Marks, Kevin P, et al.
Publicado: (2023)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
por: Torre, Enrico, et al.
Publicado: (2020)

Parental diabetes distress is a stronger predictor of child HbA1c than diabetes device use in school-age children with type 1 diabetes
por: Patton, Susana R, et al.
Publicado: (2023)

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
por: Yu, Miao, et al.
Publicado: (2020)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Inpatient HbA1c testing: a prospective observational study
por: Nanayakkara, Natalie, et al.
Publicado: (2015)

HbA(1c) and the Prediction of Type 2 Diabetes in Children and Adults
por: Vijayakumar, Pavithra, et al.
Publicado: (2017)

Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
por: Patel, Hiren, et al.
Publicado: (2019)

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
por: Gallwitz, Baptist, et al.
Publicado: (2017)

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019)

RP rewind
Publicado: (2020)

Performance of HbA(1c) and Fasting Plasma Glucose in Screening for Diabetes in Patients Undergoing Coronary Angiography
por: Wang, Jun-Sing, et al.
Publicado: (2013)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

Diabetes case finding in the emergency department, using HbA1c: an opportunity to improve diabetes detection, prevention, and care
por: Hng, Tien-Ming, et al.
Publicado: (2016)

Integrative health coaching: a behavior skills approach that improves HbA1c and pharmacy claims-derived medication adherence
por: Wolever, Ruth Q, et al.
Publicado: (2016)

HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
por: Bethel, M. Angelyn, et al.
Publicado: (2021)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

HbA(1c) After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes
por: Zeitler, Phil, et al.
Publicado: (2015)

Glucose Regulation Beyond HbA(1c) in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort
por: den Braber, Niala, et al.
Publicado: (2021)

Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program
por: Sakane, Naoki, et al.
Publicado: (2014)

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA(1c), and Insulin Dose
por: Hao, Wei, et al.
Publicado: (2016)

Unwinding and Rewinding: Double Faces of Helicase?
por: Wu, Yuliang
Publicado: (2012)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Rewinding the waves: tracking underwater signals to their source
por: Kadri, Usama, et al.
Publicado: (2017)

Mistreatment in Residency: Intervening With the REWIND Communication Tool
por: Pang, Joyce, et al.
Publicado: (2022)

Visit-to-visit HbA1c and glucose variability and the risks of macrovascular and microvascular events in the general population
por: Jang, Ji-Yong, et al.
Publicado: (2019)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_825jps9a74ksq92j6sgav9v1je